Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi
As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 months, our portfolio companies progressed greatly.
ABM Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ABM-1310 in China
On September 16, 2022, ABM Therapeutics, a clinical-stage biopharmaceutical company that is invested and incubated by Viva BioInnovator, announced that the first patient has been successfully dosed with ABM-1310 in a multi-center phase I clinical trial in China.
ABM-1310, ABM Therapeutic’s proprietary clinical candidate developed as a next-generation BRAF inhibitor, is a highly selective, highly water-soluble, orally administrated, and brain-penetrant small molecule BRAF inhibitor. ABM-1310 phase I trial, conducted in China, is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ABM-1310 in Chinese patients with BRAF V600X mutated advanced solid tumors.
F5 Therapeutics awarded First Servier FAST Discovery Award
F5 Therapeutics, which invested and incubated by Viva BioInnovator, was recently awarded the first Servier FAST Discovery Award. Winning this award means F5 stood out from 23 applications, indicating the industry’s recognition of F5’s innovative treatment methods in the field of biomedicine. “Servier FAST Discovery Award” is co-sponsored by Servier and the California Life Sciences Association (CLSA) to support early-stage life science companies using innovative approaches in areas designated by the group: oncology, auto-immune diseases, genetically driven neurodegenerative, and movement disorders.
F5 is transforming targeted protein degradation to advance drug discovery by utilizing the cell’s normal protein regulation systems to remove disease-causing proteins that cannot be targeted by traditional approaches. The NExMods™ Platform (NEosubstrate Expression Modulators) represents a novel approach to “molecular glues” capable of delivering effective medicines to patients across diverse therapeutic areas: oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration.
AceLink Therapeutics Receives Orphan Drug Designation for its Novel GCS inhibitor AL01211 for the Treatment of Fabry Disease
AceLink Therapeutics, Inc. (AceLink), invested and incubated by Viva BioInnovator, is an innovative biopharmaceutical company developing transformative therapies for genetic diseases. On September 7, 2022, they announced that they received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for AL01211 as a treatment for Fabry Disease.
AL01211 was selected based on its unique properties to effectively treat peripheral organs that Fabry disease affects by reducing the risk of off-target effects by preventing the crossing of the blood-brain barrier.
HAYA Therapeutics won the “TOP 100 Swiss Startup Award 2022” and was successfully selected for the “Soonicorn Club 2022”
On Sept. 7th, 2022, the “Top 100 Swiss Startup Award 2022,” sponsored by Venturelab, was announced. HAYA Therapeutics, invested and incubated by Viva BioInnovator, was named TOP100 Swiss Startups’ 8th Best Startup and came first in the Cardiovascular & Drug Discovery sectors. In addition, HAYA Therapeutics was recently included in the”SoonicornClub 2022″, which names the top Swiss technology startups. The awards given demonstrate the industry’s recognition of their potential in the field of biomedicine.
Regenacy Pharmaceuticals Announces Completion of Enrollment for their Phase 2 Study in Diabetic Peripheral Neuropathy and $9.3 Million in Series B Financing
Regenacy Pharmaceuticals Inc, invested and incubated by Viva BioInnovator, is a clinical-stage, biopharmaceutical company developing breakthrough treatments for diabetes and other peripheral neuropathies. On August 24, 2022, they announced completion of enrollment for the company’s phase 2 study of ricolinostat, an oral selective deacetylase 6 (HDAC6) inhibitor for painful diabetic peripheral neuropathy (DPN). The company also announced the closing of a $9.3 million Series B financing led by Cobro Ventures.
Arthrosi Completes AR882 Renal Impairment Study and its Phase 2b Study Enrollment
Arthrosi Therapeutics, Inc., which invested and incubated by Viva BioInnovator, is a clinical-stage biotechnology company focused on the treatment and management of gout. On August 9, 2022, they announced the completion of their renal impairment study that utilizes the lead compound, AR882. AR882 is a potent and selective uricosuric agent which has shown effectiveness in lowering serum urate in patients with normal renal function and in patients with mild to severe renal impairment.
On Aug. 23, 2022, Arthrosi announced the completion of enrollment for its global Phase 2b clinical study of AR882 for the treatment of chronic gout. The study, which exceeded the initial target enrollment of 120 patients, is designed to evaluate the safety and efficacy of AR882 in chronic gout patients who meet ACR/EULAR gout classification.
